Assessing Inflammation in Acute Intracerebral Hemorrhage with PK11195 PET and Dynamic Contrast-Enhanced MRI

DOI:
10.1111/jon.12477

Document Version
Accepted author manuscript

Link to publication record in Manchester Research Explorer

Citation for published version (APA):

Published in:
Journal of Neuroimaging

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Assessing inflammation in acute intracerebral hemorrhage with PK11195 PET and dynamic contrast-enhanced MRI

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Journal of Neuroimaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>JON-17-5003.R1</td>
</tr>
<tr>
<td>Wiley - Manuscript type:</td>
<td>Short Communication</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>19-Sep-2017</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Abid, Kamran; University of Manchester, Division of Neuroscience and Experimental Psychology; Salford Royal Hospital, Greater Manchester Neurosciences Centre  
Sobowale, Oluwaseun; University of Manchester, Division of Neuroscience and Experimental Psychology; Salford Royal Hospital, Greater Manchester Neurosciences Centre  
Parkes, Laura; University of Manchester, Division of Neuroscience and Experimental Psychology  
Naish, Josephine; University of Manchester Institute of Cardiovascular Sciences  
Parker, Geoff; University of Manchester, Division of Informatics, Imaging and Data Sciences; Bioxydyn Limited, Rutherford House, Pencroft Way  
Duplessis, Daniel; Salford Royal Hospital, Greater Manchester Neurosciences Centre  
Brough, Daniel; University of Manchester, Division of Neuroscience and Experimental Psychology  
Barrington, Jack; University of Manchester Institute of Cardiovascular Sciences  
Allan, Stuart; University of Manchester, Division of Neuroscience and Experimental Psychology  
Hinz, Rainer; The University of Manchester, Wolfson Molecular Imaging Centre  
Parry-Jones, Adrian; University of Manchester Institute of Cardiovascular Sciences; Salford Royal Hospital, Greater Manchester Neurosciences Centre |
| Keywords:         | intracerebral haemorrhage, inflammation, blood-brain barrier, magnetic resonance imaging, positron emission tomography |
| Subject Area:     | Imaging Techniques < NEUROIMAGING, Magnetic Resonance Imaging (MRI) < Magnetic Resonance (MR) < Imaging Techniques < NEUROIMAGING, Positron Emission Tomography (PET) < Imaging Techniques < NEUROIMAGING |
Assessing inflammation in acute intracerebral hemorrhage with PK11195 PET and dynamic contrast-enhanced MRI

Imaging inflammation in acute intracerebral hemorrhage: a combined $^{11}$C (R)-PK11195 PET and DCE-MRI study

Kamran A Abid PhD$^{1,3,*}$, Oluwaseun A Sobowale MRCS$^{1,3,*}$, Laura M Parkes PhD$^1$,
Josephine Naish PhD$^1$, Geoff JM Parker PhD$^{1,2}$, Daniel du Plessis FRCP$^3$, David Brough PhD$^1$, Jack Barrington BSc$^1$, Stuart M Allan PhD$^1$, Rainer Hinz PhD$^1$, Adrian R Parry-Jones PhD$^{1,3}$

$^1$Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK;

$^2$Bioxydyn Limited, Manchester, UK;

$^3$Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust, Salford, Manchester, UK.

*Contributed equally

Corresponding Author:
Dr A.R. Parry-Jones
Salford Royal NHS Foundation Trust, Stott Lane
Salford, M6 8HD, UK

E-mail: adrian.parry-jones@manchester.ac.uk
Tel: +44 161 2064458
Fax: +44 161 7076534

Running title: Multimodality imaging of brain inflammation in ICH

Key words: Intracerebral haemorrhage, inflammation, blood-brain barrier, magnetic resonance imaging, positron emission tomography
Acknowledgements: none.

Disclosures: none.
Abstract

**Background and purpose:**

Studies in animal models have suggested that inflammation is a major contributor to secondary injury after intracerebral haemorrhage (ICH). Direct, non-invasive monitoring of inflammation in the human brain after ICH will facilitate early-phase development of anti-inflammatory treatments. We sought to investigate the feasibility of multi-modality brain imaging in subacute ICH.

**Methods:**

Acute ICH patients were recruited to undergo multiparametric magnetic resonance imaging (MRI) (including dynamic contrast enhanced measurement of blood-brain barrier transfer constant ($K_{\text{trans}}$) and positron emission tomography (PET) with $[^{11}\text{C}]-(R)$-PK11195. $[^{11}\text{C}]-(R)$-PK11195 binds to the translocator protein 18 kDa (TSPO), which is rapidly upregulated in activated microglia. Circulating inflammatory markers were measured at the time of PET.

**Results:**

Five patients were recruited to this feasibility study with imaging performed between 5 and 16 days after onset. Etiologies included hypertension-related small vessel disease, cerebral amyloid angiopathy (CAA), cavernoma and arteriovenous malformation (AVM). $[^{11}\text{C}]-(R)$-PK11195 binding was low in all hematomas and two patients (probable CAA) and patient 4 (AVM) showed widespread increase in binding in the perihematomal region vs. contralateral. All had increased $K_{\text{trans}}$ in the perihematomal region (mean difference = 2.2 x $10^{-3}$ min$^{-1}$; SD = 1.6 x $10^{-3}$ min$^{-1}$) vs. contralateral. Two cases (patients 1 (cavernoma) and 4 (AVM)) showed widespread increase in binding in the perihematomal region vs. contralateral.
(AVM) had delayed surgery (three and 12-months post-onset, respectively) with biopsies showing intense microglial activation in perilesional tissue.

Conclusions:

Our study demonstrates for the first time the feasibility of performing complex multi-modality brain imaging for non-invasive monitoring of neuroinflammation for this severe stroke subtype. These techniques will be useful tools in developing anti-inflammatory treatments for clinical ICH.
Introduction

After intracerebral hemorrhage (ICH), extravasation of blood leads to immediate physical tissue injury. Secondary damage ensues over hours and days, mediated by a cascade of molecular and cellular events involving the toxic effects of blood components and sterile inflammation. Within hours of onset, microglia become activated taking on a pro-inflammatory phenotype, releasing cytokines and chemokines that activate astrocytes and endothelial cells causing blood-brain barrier (BBB) breakdown (alongside the direct effects of the ICH), recruitment of circulating leukocytes, and exacerbation of perihematomatal edema. Previous clinical studies in ICH have largely focused on peripheral inflammatory markers showing associations between fever, elevated white blood cell count, interleukin-6 (IL-6), C-reactive protein (CRP), and fibrinogen on admission and worse sub-acute and long-term outcomes. These clinical studies demonstrate the importance of the systemic inflammatory response, but provide no information on processes within the brain, where inflammation contributes directly to secondary injury. Given the growing interest in modulating inflammation in acute ICH and the failure in ischemic stroke to translate findings from animal models, a means of studying inflammation in the intact human brain after ICH is urgently required.

Using advanced multimodality imaging, it is possible to estimate the extent and distribution of microglial activation and BBB breakdown. When activated, microglia express the translocator protein 18 kDa (TSPO), normally present at very low levels in the central nervous system. [$^{11}$C]-(R)-PK11195 binds to TSPO and has been used for positron emission tomography (PET) studies of acute ischemic stroke, but in vivo imaging of microglial activation in ICH has not been previously described. Using magnetic resonance imaging (MRI) and computed tomography (CT) dynamic contrast enhanced (DCE) techniques, two previous studies have quantified BBB breakdown after ICH. Combining this
technique with $^{[11]}$C-(R)-PK11195 PET will provide a more complete picture of the inflammatory response and allow an understanding of the extent that BBB breakdown colocalizes with microglial activation with important implications for the delivery of an anti-inflammatory drug to the brain. Our aim was to demonstrate the feasibility of combining these techniques in patients during the acute stage of ICH and describe hypothesis-generating preliminary findings.

**Methods**

Patients between 4 and 28 days after onset of acute, spontaneous ICH were recruited from Salford Royal NHS Foundation Trust (Salford, UK) between 05/12/12 and 28/03/2014, following appropriate approvals. We excluded patients if they had a contraindication to MRI, were pregnant or breast feeding, had significant renal impairment, had an acute neurosurgical procedure performed or planned or who were taking medications which were likely to interfere with $^{[11]}$C-(R)-PK11195 binding. MRI was performed on a Philips 3 T Achieva scanner (Salford Royal Hospital) with an 8 channel head coil. PET scans were performed within 4 days of MRI on a High Resolution Research Tomograph (Siemens/CTI) PET scanner (Wolfson Molecular Imaging Centre, University of Manchester). Venous blood was collected at recruitment (where possible) and immediately prior to the PET scan for measurement of key inflammatory mediators (CRP, IL-6, interleukin-1 (IL-1); see online supplement for immunoassay methods).

MRI included T$_1$-weighted volumetric Fast Field Echo (T$_1$-FFE) imaging, T$_2$-weighted fluid attenuated inversion recovery (FLAIR) imaging and T$_1$-weighted DCE-MRI. Parametric maps of the blood-brain barrier transfer constant ($K^{\text{trans}}$) were generated from DCE-MRI data using an uptake model (details of MRI acquisition and analysis in online supplementary
methods). PET data were analyzed as previously described[7]. In brief, iterative ordered subset expectation maximization 3D method was used to reconstruct a quantitative series of dynamic images from the 60 min PET emission scan. A reference tissue input function was extracted from cerebellar grey matter in order to generate parametric maps of binding potential $BP_{ND}$ using the simplified reference tissue model. Using SPM (version 8), all maps and images were co-registered to the $T_1$-weighted volume MRI. The $T_1$-weighted volume image was segmented into grey matter and white matter probability maps and a maximum probability brain atlas[8] was warped in to individual space. Two regions of interest (ROI) were defined manually from the $T_1$-weighted and FLAIR images, representing hematoma and perihematomal edema. Corresponding ROIs in the contralateral brain region were generated by flipping the ipsilateral ROIs about the midline in the axial plane excluding any non-brain tissue. The mean binding potential ($BP_{ND}$) of $[^{11}C]-(R)-PK11195$ and $K^{trans}$ within each ROI was then extracted from the parametric maps using Analyze version 12.0 (Mayo Clinic).

Results

Five patients with acute ICH underwent research brain imaging between 5 and 25 days after onset as part of this feasibility study (Table 1). All patients tolerated the scans without difficulty except patient 3, who was unable to complete the last 22 min of the 60 min emission PET scan and was the only one to undergo both scans on one day. Etiologies confirmed using appropriate clinical imaging included a cavernous angioma, an arteriovenous malformation (Figure 1), probable cerebral amyloid angiopathy and small vessel disease due to chronic hypertension. $[^{11}C]-(R)-PK11195$ binding was low in all hematomas. Patients 2 & 4 showed increased $[^{11}C]-(R)-PK11195$ binding both within the perihematomal edema volume (0.24 and 0.06 respectively, vs. contralateral) and the ipsilateral brain region (0.13 &
Analyses of DCE-MRI data show increases in $K_{\text{trans}}$ in the perihematomal edema volume (mean difference = $2.2 \times 10^{-3}$ min$^{-1}$; SD = $1.6 \times 10^{-3}$ min$^{-1}$) in all 5 patients relative to the contralateral. Visual inspection of images (Figure 2) consistently demonstrates a clear ring of increased $K_{\text{trans}}$ adjacent to the outer border of the hematoma. No pattern is suggested for a relationship between circulating inflammatory markers and imaging, though for all cases, CRP was lower at the time of PET scanning than at recruitment.

Discussion

Our small study is the first to show imaging of microglial activation with PET after ICH and demonstrates the feasibility of performing complex multimodality brain imaging after acute ICH. However, we found that performing PET and MR scans on different days may improve successful study completion. All patients show clear ring-shaped BBB breakdown in the outer border of the hematoma, suggesting that delivery of treatments with limited transfer across the intact BBB may be enhanced in acute ICH. We observed a heterogeneous pattern of $[^{11}C]-(R)$-PK11195 binding, with only two patients demonstrating enhanced binding around the hematoma. In neither case was the binding closely co-located with the BBB disruption, suggesting that factors other than microglial activation may drive BBB breakdown after ICH, an observation that should be investigated further in future studies.

Late perilesional biopsies in two patients did show intense microglial activation, but only one had enhanced $[^{11}C]-(R)$-PK11195 binding acutely. The long delay between PET and biopsies makes it difficult to interpret this disparity.

Summary/Conclusions
We have demonstrated the feasibility of performing complex multimodality imaging to track the inflammatory response after ICH. This will be a vital tool in investigating this promising therapeutic target with potential use in early phase proof-of-concept clinical trials.

References

Table 1. Baseline characteristics, inflammatory markers and imaging data.

<table>
<thead>
<tr>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline Characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>30</td>
<td>63</td>
<td>85</td>
<td>43</td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>GCS at presentation</td>
<td>14</td>
<td>15</td>
<td>15</td>
<td>14</td>
</tr>
<tr>
<td>ICH etiology</td>
<td>Cavernous angioma&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Probable CAA&lt;sup&gt;1&lt;/sup&gt;</td>
<td>undetermined primary</td>
<td>Arteriovenous malformation&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>ICH location</td>
<td>Right temporal</td>
<td>Right occipital</td>
<td>Left cerebellar parietal</td>
<td>Left lentiform</td>
</tr>
<tr>
<td>ICH volume (ml)</td>
<td>6.1</td>
<td>6.7</td>
<td>8.5</td>
<td>30.0</td>
</tr>
<tr>
<td>PHE volume (ml)</td>
<td>4.3</td>
<td>6.9</td>
<td>5.2</td>
<td>15.9</td>
</tr>
<tr>
<td>PET scan (days post-onset)</td>
<td>7</td>
<td>11</td>
<td>25</td>
<td>16</td>
</tr>
<tr>
<td>MR scan (days post-onset)</td>
<td>9</td>
<td>10</td>
<td>25</td>
<td>12</td>
</tr>
<tr>
<td><strong>Inflammatory mediators</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-1β baseline (pg/ml)</td>
<td>-</td>
<td>-</td>
<td>0.56</td>
<td>0.63</td>
</tr>
<tr>
<td>PET scan (pg/ml)</td>
<td>0.81</td>
<td>1.07</td>
<td>1.90</td>
<td>1.94</td>
</tr>
<tr>
<td>IL-6 baseline (pg/ml)</td>
<td>-</td>
<td>-</td>
<td>7.77</td>
<td>2.35</td>
</tr>
<tr>
<td>PET scan (pg/ml)</td>
<td>3.82</td>
<td>&lt;0.012</td>
<td>4.29</td>
<td>1.5</td>
</tr>
<tr>
<td>IL-8 baseline (pg/ml)</td>
<td>-</td>
<td>-</td>
<td>16.97</td>
<td>16.12</td>
</tr>
<tr>
<td>PET scan (pg/ml)</td>
<td>11.53</td>
<td>4.84</td>
<td>15.77</td>
<td>10.66</td>
</tr>
<tr>
<td>CRP baseline (mg/l)</td>
<td>-</td>
<td>-</td>
<td>2.80</td>
<td>4.32</td>
</tr>
<tr>
<td>PET scan (mg/l)</td>
<td>0.472</td>
<td>0.598</td>
<td>0.862</td>
<td>0.85</td>
</tr>
<tr>
<td><strong>DCE-MRI parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean K&lt;sub&gt;trans&lt;/sub&gt; (x 10&lt;sup&gt;-3&lt;/sup&gt; min&lt;sup&gt;-1&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perihematomal edema</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipsilateral</td>
<td>1.8</td>
<td>5.7</td>
<td>2.1</td>
<td>2.9</td>
</tr>
<tr>
<td>Contralateral</td>
<td>0.4</td>
<td>0.7</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Ipsilateral - contralateral</td>
<td>1.4</td>
<td>5.0</td>
<td>1.0</td>
<td>1.9</td>
</tr>
</tbody>
</table>

Table 1: Baseline characteristics, inflammatory markers and imaging data.  
<sup>1</sup>Based on modified Boston criteria; <sup>2</sup>Confirmed on histology at later surgical resection.  
ICH = intracerebral haemorrhage, pg = picogram, ml = millilitre, l = litre, mg = milligram, GCS = Glasgow Coma Scale.
Glasgow Coma Scale, PHE = peri-haematoma edema, CRP = C-reactive protein, DCE = dynamic contrast-enhanced, $K_{\text{trans}}$ = volume transfer constant, IL = interleukin, CAA = cerebral amyloid angiopathy.

Figure legends

Figure 1: Cluster of differentiation 68CD68 immunostaining (original magnification x400) demonstrates diffuse microglial activation (2a) in patient 1 (suspected cavernoma) and activated microglia and phagocytic activity (2b) in patient 4 (arteriovenous malformation AVM).

Figure 2: Representative parametric maps of $[^{11}\text{C}](R)$-PK11195 PET binding potential ($BP_{\text{ND}}$) (superimposed on to $T_1$-weighted images) and volume transfer constant ($K_{\text{trans}}$) with Fluid-attenuated inversion recovery (FLAIR) FLAIR images from each patient with regions of interest ROIs for hematoma (green) and edema (red). Increased $[^{11}\text{C}](R)$-PK11195 binding is indicated in patients 2&4 by arrows.
Cluster of differentiation 68 immunostaining (original magnification x400) demonstrates diffuse microglial activation (2a) in patient 1 (suspected cavernoma) and activated microglia and phagocytic activity (2b) in patient 4 (arteriovenous malformation).
Representative parametric maps of [11C]-(R)-PK11195 PET binding potential (BPND) (superimposed on to T1-weighted images) and volume transfer constant (Ktrans) with Fluid-attenuated inversion recovery (FLAIR) images from each patient with regions of interest for hematoma (green) and edema (red). Increased [11C]-(R)-PK11195 binding is indicated in patients 2&4 by arrows.

1280x750mm (96 x 96 DPI)